STANDSTILL AGREEMENTStandstill Agreement • August 14th, 2023 • Astellas US LLC • Biological products, (no disgnostic substances) • Delaware
THIS STANDSTILL AGREEMENT (“Agreement”) is being entered into as of August 4, 2023, by and between Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), and Astellas US, LLC, a Delaware corporation (“Counterparty”). Each of the Company and Counterparty are referred to collectively as the “Parties” and individually as a “Party”.
JOINT FILING AGREEMENTJoint Filing Agreement • August 14th, 2023 • Astellas US LLC • Biological products, (no disgnostic substances)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
